Loncastuximab tesirine - Wikipedia
Loncastuximab tesirine, sold under the brand name Zynlonta, is a monoclonal antibody conjugate medication used to treat large B-cell lymphoma and high-grade B-cell lymphoma. [1] [2] It is an antibody-drug conjugate (ADC) composed of a humanized antibody targeting the protein CD19. [1]
r/r DLBCL Treatment | ZYNLONTA® (loncastuximab tesirine-lpyl) …
ZYNLONTA® (loncastuximab tesirine) is a therapy for adults with diffuse large B-cell lymphoma after at least 2 therapies. See Important Risk Info. Rx Only.
FDA grants accelerated approval to loncastuximab tesirine-lpyl …
On April 23, 2021, the Food and Drug Administration granted accelerated approval to loncastuximab tesirine-lpyl (Zynlonta, ADC Therapeutics SA), a CD19-directed antibody and alkylating agent...
Loncastuximab tesirine in relapsed or refractory diffuse large B …
2021年5月11日 · Loncastuximab tesirine has substantial single-agent antitumour activity and produces durable responses with an acceptable safety profile, potentially offering a new therapeutic option for heavily pretreated patients with relapsed or refractory DLBCL.
Loncastuximab tesirine in relapsed or refractory diffuse large B …
Loncastuximab tesirine is a CD19-directed antibody-drug conjugate with encouraging phase 1 single-agent antitumour activity and acceptable safety in non-Hodgkin lymphoma. We aimed to evaluate the antitumour activity and safety of loncastuximab tesirine in patients with relapsed or refractory DLBCL.
R/R DLBCL Treatment | ZYNLONTA® (loncastuximab tesirine-lpyl) …
2022年4月1日 · ZYNLONTA® (loncastuximab tesirine-lpyl) is a treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma after 2 or more lines of systemic therapy.
The antibody-drug conjugate loncastuximab tesirine for the …
2022年7月28日 · Loncastuximab tesirine is a cluster of differentiation19-targeting antibody-drug conjugate approved by the US Food and Drug Administration for relapsed DLBCL after 2 lines of systemic therapy based on a trial showing a 48.3% overall response rate.
Loncastuximab Tesirine-lpyl - NCI - National Cancer Institute
Loncastuximab tesirine-lpyl is approved to treat: Diffuse large B-cell lymphoma (DLBCL). DLBCL in patients who had low-grade lymphoma. High-grade B-cell lymphoma. It is used in adults whose cancer has relapsed (come back) or has not gotten better after at …
Loncastuximab tesirine-lpyl (intravenous route) - Mayo Clinic
2024年1月31日 · Loncastuximab tesirine-lpyl injection is to treat large B-cell lymphoma (including diffuse large B-cell lymphoma [DLBCL], high grade B-cell lymphoma, or DLBCL from low grade lymphoma) that has come back or did not respond to previous treatment in patients who have received 2 or more other medicines did not work well.
Loncastuximab | Leukemia and Lymphoma Society
Loncastuximab tesirine-lpyl is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma.